Latest news
BioCryst Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $20.82, Implies 131% Upside - TradingViewTradingView · Wed, 05 Aug 2026 21:20:08 GMTBCRX: Q2 revenue up 45% year-over-year, with robust ORLADEYO growth and strong cash position - TradingViewTradingView · Wed, 05 Aug 2026 14:14:05 GMTBioCryst Pharmaceuticals Q2 Earnings Call Highlights - TradingViewTradingView · Wed, 05 Aug 2026 14:04:29 GMTBioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Wed, 05 Aug 2026 13:31:59 GMTBCRX: Q2 2026 delivered robust revenue and profit growth, with raised guidance and pipeline progress - TradingViewTradingView · Wed, 05 Aug 2026 11:25:16 GMTBioCryst Pharmaceuticals Q2 revenue rises, lifts 2026 revenue guidance - TradingViewTradingView · Wed, 05 Aug 2026 11:23:57 GMTBCRX: Q2 2026 delivered robust revenue and profit growth, with a strong outlook for the HAE franchise - TradingViewTradingView · Wed, 05 Aug 2026 11:06:37 GMTBCRX Q2'26 Earnings: EPS estimate is 0.15 USD - TradingViewTradingView · Tue, 04 Aug 2026 11:01:01 GMT